share_log

Cantor Fitzgerald Reiterates Overweight on Keros Therapeutics

Benzinga ·  Nov 22 09:24

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Keros Therapeutics (NASDAQ:KROS) with a Overweight.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment